This inventor holds 2 USPTO granted patents. Top assignees: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory, Hitgen, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Fei Qin: Pharmaceutical Inventions and Patent Contributions
Introduction
Fei Qin is an inventor based in Guangzhou, China, whose work focuses on pharmaceutical compounds, drug synthesis, and their potential applications. His listed portfolio includes 2 patents.
Latest Patents
- Piperazine Derivatives and Application Thereof. This patent describes a class of piperazine derivatives, including a compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and its application.
- Crystal Form of Macrocyclic Compound, and Preparation Method Therefor and Use Thereof. This invention concerns a crystal form of a macrocyclic compound and its preparation and use. The compound is identified as (6R,16R)-9-fluoro-16-methyl-13-oxa-2,17,21,25-tetraazapentane[16.6.2.0⁰⁰]dihexadecane-1(25),7,9,11,18(26),19,21,23-octane-19-carbonitrile. Its X-ray diffraction pattern includes characteristic peaks at specified 2θ values from 9.49±0.2 to 27.74±0.2. The patent describes the crystal form as non-hygroscopic, stable, and having favorable pharmacokinetic properties.
Career Highlights
Fei Qin has been associated with HitGen, Inc. and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory. These organizations are connected to pharmaceutical research and development, providing context for his work on drug-related inventions.
Collaborations
His listed coworkers include Jiansong Wang and Zhibo Luo, reflecting professional connections within pharmaceutical research and invention.
Conclusion
Fei Qin’s patent work addresses pharmaceutical compounds and crystal-form development, with inventions focused on preparation, stability, and potential drug applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile